The role of sulfonylureas in the treatment of type 2 diabetes

Brian Tomlinson, Nivritti Gajanan Patil, Manson Fok, Paul Chan, Christopher Wai Kei Lam

研究成果: 雜誌貢獻文章同行評審

摘要

Introduction: Type 2 diabetes (T2D) is increasingly prevalent and associated with increased risk for cardiovascular and renal disease. After lifestyle modification, metformin is usually the first-line pharmacotherapy and sulfonylureas are traditionally added after metformin failure. However, with newer glucose lowering drugs that may have less risk of hypoglycemia or that may reduce cardiovascular and renal events, the position of sulfonylureas is being reevaluated. Areas covered: In this article, the authors review relevant publications related to the use of sulfonylureas. Expert opinion: Sulfonylureas are potent glucose lowering drugs. The risk of hypoglycemia varies with different drugs within the class and can be minimized by using the safer drugs, possibly in lower doses. Cardiovascular events do not appear to be increased with some of the newer generation drugs. The durability of glycemic control also appears comparable to other newer agents. Sulfonylureas are the preferred treatment for some types of monogenic diabetes and selection of T2D patients who may have greater benefit from sulfonylureas based on certain phenotypes and genotypes is likely to be refined further by precision medicine. Sulfonylureas are inexpensive and readily available everywhere and they are still the most frequently used second-line treatment for T2D in many parts of the world.
原文英語
頁(從 - 到)387-403
頁數17
期刊Expert Opinion on Pharmacotherapy
23
發行號3
DOIs
出版狀態已發佈 - 2022

ASJC Scopus subject areas

  • 藥理
  • 藥學(醫學)

指紋

深入研究「The role of sulfonylureas in the treatment of type 2 diabetes」主題。共同形成了獨特的指紋。

引用此